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Abstract
These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally
changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic
strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells,
and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called
immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal
antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1
(PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic
targets and schemes which combine various immunological agents are now being described at a breathtaking
pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive
cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the
synergistic design of immune-targeting combination therapies.
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Background
The idea of exploiting the host’s immune system to treat
cancer dates back decades and relies on the insight that
the immune system can eliminate malignant cells during
initial transformation in a process termed immune sur-
veillance [1]. Individual human tumors arise through a
combination of genetic and epigenetic changes that fa-
cilitate immortality, but at the same time create foreign
antigens, the so-called neo-antigens, which should ren-
der neoplastic cells detectable by the immune system
and target them for destruction. Nevertheless, although
the immune system is capable of noticing differences in
protein structure at the atomic level, cancer cells manage
to escape immune recognition and subsequent destruc-
tion. To achieve this, tumors develop multiple resistance
mechanisms, including local immune evasion, induction
of tolerance, and systemic disruption of T cell signaling.
Moreover, in a process termed immune editing, immune
recognition of malignant cells imposes a selective pressure
on developing neoplasms, resulting in the outgrowth of
less immunogenic and more apoptosis-resistant neoplastic
cells [2].
Scientists have known for decades that cancer cells are
particularly efficient at suppressing the body’s natural
immune response, which is why most treatments exploit
other means, such as surgery, radiation therapy and
chemotherapy, to eliminate neoplastic cells. It is now
established that various components of the immune system
play pivotal roles in protecting humans from cancer. Fol-
lowing numerous disappointing efforts and unequivocal
clinical failures, the field of cancer immunotherapy has re-
cently received a significant boost, encouraged primarily by
the approval of the autologous cellular immunotherapy,
sipuleucel-T, for the treatment of prostate cancer in 2010
[3] and the approval of the anti-cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) antibody, ipilimumab, and
of anti-programmed cell death protein 1 (PD1) antibodies
for the treatment of melanoma in 2011 and 2014, [4]
respectively. These successes have revitalized the field
and brought attention to the opportunities that immu-
notherapeutic approaches can offer [5].
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Immunotherapies against existing cancers include various
approaches, ranging from stimulating effector mechanisms
to counteracting inhibitory and suppressive mechanisms
(Table 1). Strategies to activate effector immune cells in-
clude vaccination with tumor antigens or augmentation of
antigen presentations to increase the ability of the patient’s
own immune system to mount an immune response
against neoplastic cells [6]. Additional stimulatory strategies
encompass adoptive cellular therapy (ACT) in an attempt
to administer immune cells directly to patients, the ad-
ministration of oncolytic viruses (OVs) for the initiation
of systemic antitumor immunity, and the use of anti-
bodies targeting members of the tumor necrosis factor
receptor superfamily so as to supply co-stimulatory sig-
nals to enhance T cell activity. Strategies to neutralize
immunosuppressor mechanisms include chemotherapy
(cyclophosphamide), the use of antibodies as a means
to diminish regulatory T cells (CD25-targeted antibodies),
and the use of antibodies against immune-checkpoint
molecules such as CTLA-4 and PD1. This review summa-
rizes the main strategies in cancer immunotherapy and
discusses recent advances in the design of synergistic com-
bination strategies [1].
Vaccines
Historically, the primary approach to specifically activate
host T cells against tumor antigens has been therapeutic
cancer vaccination. In addition to the successful use of
preventative vaccines used in the defense against cancer-
causing infectious diseases, including hepatitis B virus
and human papillomavirus, the knowledge that patients
can harbor CD8+ and CD4+ T cells capable of recogniz-
ing tumor expressed antigens hinted at the possibility of
developing cancer vaccines [5, 7].
Unfortunately, the general lack of understanding of
the mechanisms of immunization, and particularly of the
role of dendritic cells (DCs), has led to a series of fail-
ures of therapeutic cancer vaccines in initial randomized
trials [5, 8]. Early on, it was not appreciated that, by creat-
ing an environment that disables the immune response,
cancer is able to induce tolerance. Therefore, in contrast to
conventional prophylactic vaccines for infectious agents, in
Table 1 The spectrum of available immunotherapies
Strategy Basic mechanism and major advantages Major disadvantages Reference
Cytokines
IL-2 -Stimulates the host’s immune system -Low response rates
-Significant risk of serious systemic
inflammation
[1]
IFN-α -Stimulates the host’s immune system






Vaccines -Stimulates the host’s immune system
-Minimal toxicity (e.g., sipuleucel-T)
-Administered in the outpatient clinic
-Lack of universal antigens and ideal
immunization protocols lead to poor
efficacy and response
[6]
Adoptive cellular therapy -Omits the task of breaking tolerance
to tumor antigens
-Produces a high avidity in effector
T cells
-Lymphodepleting conditioning regimen
prior to TIL infusion enhances efficacy
-Genetic T cell engineering broadens TIL
to malignancies other than melanoma
-Restricted to melanoma
-Safety issues, serious adverse effects, and lack
of long lasting responses in many patients
-Requires time to develop the desired cell
populations
-Expensive
[5, 27, 60, 62–
64, 68–70]
Immune checkpoint blockade
Anti-CTLA-4 monoclonal antibodies -Unleashes pre-existing anticancer T cell
responses and possibly triggers new
-Exhibits potent antitumor properties
-Prolongation of overall survival
-Only a relatively small fraction of patients
obtain clinical benefit
-Severe immune-related adverse events have
been observed in up to 35 % of patients
[5, 13, 76, 77]
Anti-PD1 and anti-PD-L1 antibodies -Sufficient clinical responses which are
often long-lasting
-Therapeutic responses in patients within
a broad range of human cancers
-Reduced toxicity compared to anti-CTLA-4
antibodies




checkpoint blockade as the backbone)
-Improvement of anti-tumor responses/
immunity
-May lead to increases in the magnitude,
frequency, and onset of side effects
[9, 10]
IL-2, Interleukin 2; IFN-α, Interferon-alpha; CTLA-4, Cytotoxic T lymphocyte-associated protein 4; PD1, Programmed cell death protein 1;
TIL, Tumor infiltrating antibodies
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order to be effective, cancer vaccination must break the tol-
erance acquired by the tumor cells [3, 5, 9]. DCs are known
to be the most effective antigen presenting cells and play a
pivotal role in coordinating innate and adaptive immune re-
sponses [10]. Thus, for cancer vaccines to break the toler-
ance, high quantities of antigens must be targeted to DCs
and these, in turn, need to be expanded and activated with
appropriate agents [3].
One of the main obstacles to the development of suc-
cessful cancer vaccines is in identification of the most
suitable antigens to use [11]. The earlier vaccine formu-
lations which consisted of short peptides, (usually with-
out an effective DC-activating adjuvant) resulted in
minimal clinical effectiveness. This could be attributed
to their poor pharmacokinetic properties leading to their
rapid clearance before being loaded onto DCs. Without
an appropriate activation signal, DCs would probably
remain in the steady state and be as likely to induce
tolerance as immunity [8]. As it was later shown, the
therapeutic efficacy of cancer vaccines can be improved
when immune stimulants such as IL-2 are co-administered
with short peptide vaccines [12]. However, in some studies,
the combination of a cancer vaccine with an immune
checkpoint blockade demonstrated no improvement over
the blockade alone [13]. Since full-length proteins harbor a
wider profile of epitopes that could be presented by DCs,
they have also been tested as targets for cancer vaccinations
[5]. Preliminary data from a phase II trial that used a re-
combinant fusion protein encoding a single cancer-testis
antigen (melanoma antigen family A3; MAGE-A3) in
HLA-A2-positive non-small cell lung cancer (NSCLC)
patients, failed to show a statistically significant survival
response [14]. However, it should be noted that, although
MAGE-A3 expression was assessed in these patients, the
level of homogeneity of MAGE-A3 expression was not re-
ported. This is crucial because T cell response would have
to diversify to additional cancer antigens in order to evoke
immune attack on those subpopulations of lung cancer
cells that do not express MAGE-A3 [5]. Whole cells or cell
lysates have been exploited as polyvalent sources of tumor
antigens [3]. The rationale behind this approach is that a
cancer vaccine should contain a wide variety of tumor-
associated antigens, thus using cancer cells or their lysate,
as the vaccine would overcome the obstacle of antigen se-
lection. However, even GVAX, the most promising vaccine
product based on early studies, failed in Phase III trials due
to a lack of clinical efficacy. The failure could be attributed
to inadequate immunogenicity of the approach and alter-
ations in preparation of the vaccine product required by
commercial scale-up [15]. In addition, since cell-based
vaccines contain thousands of antigens, they have been
criticized for a lack of tumor specificity [3].
DCs are known as professional antigen presenting
cells (APCs), as they are extremely efficient at antigen
presentation and induction of T cell immunity when
compared with other APCs such as macrophages. These
properties have driven attempts to develop DC-based vac-
cines [10]. In this approach, DCs are isolated from the pa-
tient’s peripheral blood mononuclear cells (PBMC), loaded
with tumor antigens ex vivo, activated, and then reinfused
back into the patient (Fig. 1) [16, 17]. These vaccinations
have produced encouraging, albeit modest, clinical results
in some patients with advanced cancers. For instance,
treatment of metastatic prostate cancer with sipuleucel-T,
a cellular product based on enriched blood APCs briefly
cultured with a fusion protein consisting of prostatic acid
phosphatase linked to the DC growth and differentiation
factor granulocyte macrophage colony-stimulating factor
Fig. 1 Dendritic cell (DC) based vaccines. CD34+ hematopoietic progenitor cells or monocytes are isolated from the patient’s peripheral blood by
cytapheresis. Monocytes are cultured in the presence of Granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 to induce differentiation
into immature DCs, while CD34+ cells are differentiated when cultured in the presence of GM-CSF, Flt3 ligand and TNF-α. Immature DCs are then
loaded with antigen in the form of proteins, peptides or tumor cells either with or following their maturation with proinflammatory cytokines. Once
loaded with antigen, DCs can be re-introduced to the patient or frozen in aliquots and thawed before vaccination. (Adapted from [17])
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(GM-CSF), achieved an approximately 4-month improve-
ment in median survival [18, 19]. The survival benefit of
sipuleucel-T ultimately led to US Food and Drug Admin-
istration (FDA) approval in 2010 [3]. Despite this increase
in survival, randomized clinical trials of sipuleucel-T have
failed to show meaningful decreases in tumor volumes or
disease response. Furthermore, this approach has not been
widely adopted by the biotech-pharmaceutical industry,
oncologists, clinical investigators, or patients due to the
complications associated with producing and administer-
ing the therapy [5].
Obstacles to the success of cancer vaccines adminis-
tered as “single agents” are still many. The ideal tumor
antigens should not just be expressed at high levels in
the target tumor population in a significant percentage
of patients with a particular cancer type, but should also
be expressed at lower levels or not at all in normal tis-
sues to ensure specificity and should be essential for
the cancer’s growth or survival in order to minimize
the potential for immune escape due to downregulation
of antigen expression [20, 21]. Currently, not many an-
tigens fulfill these criteria and even having all of these
properties cannot assure the production of a protective
T cell response [22–24]. Additionally, it may be inadequate
to rely solely on sequencing the expressed tumor gen-
ome searching for mutations. Not only can the muta-
tional status and antigen expression within a tumor
bed be heterogeneous, but even if expressed, it is not
guaranteed that predicted antigenic peptides will be
produced and processed as peptide-major histocom-
patibility complex class I (MHCI) complexes. A few
groups have sought to address this issue by coupling
bioinformatics and mass spectroscopy of peptides eluted
from MHCI molecules from both primary tumors and cell
lines [25–27]. This strategy can indeed identify those anti-
gens that yield potential targets, but these peptide-MHCI
complexes might still not be capable of triggering potent
T cell responses. Further, even if ideal antigens are
identified, it remains unclear how best to deliver them
to patients.
The ideal vaccine will be one able to trigger the matur-
ation of DCs to a state where they can promote the produc-
tion of tumor-reactive, CD8+ cytotoxic T cells. It is possible
that conditions for immunization will finally be optimized;
however, the efficacy of a tumor-specific T cell population
may still be compromised by the numerous mechanisms of
immunoevasion exploited by tumors to defend against T
cell attack. These are not reasons to exclude vaccines from
consideration as part of an immunotherapy, but rather to
call attention to some of the limitations in assessing success
in the absence of other immunological regimes. Work on
vaccines should continue in a methodical fashion with hu-
man studies, since animal models are unlikely to illuminate
the best path forward. In addition, similar to all forms
of targeted therapy in cancer, the discovery and applica-
tion of predictive biomarkers or diagnostics, for the
identification of those patients most likely to profit
from a given vaccine, will be an important challenge for
future development [5, 11].
Oncolytic virus therapy
OV immunotherapy represents a novel form of cancer
therapy that employs native or engineered viruses that
selectively replicate in and kill cancer cells [28]. OVs are
believed to promote antitumor responses mainly through
two distinct mechanisms of action: acute tumor debulking
owing to tumor cell infection and lysis and induction/initi-
ation of systemic antitumor immunity [29].
Many of the “hallmarks of cancer”, such as sustained
proliferation, usurping cellular apoptotic programs, and
inactivating growth suppressors, described by Hanahan
and Wineberg [30], favor the selective replication of OVs
in malignant cells with minimal toxicity to normal tis-
sues [29]. What has also led to an increased interest in
employing viruses for the treatment of cancer is the fact
that the viral genome can be modified to augment anti-
tumor activity and attenuate pathogenicity [31]. Some of
the numerous modifications that have been developed
and tested include the insertion of promoters that re-
strict the expression of virulence genes to tumor cells or
the deletion of pathogenic genes to limit the growth and
lytic activity of viruses to cancer cells [32, 33]. Addition-
ally, OVs can be engineered to express specific cytokines
that favor immune cell recruitment and activation or to
produce T cell co-stimulatory molecules on infected
tumor cells, thus facilitating the generation of T cell-
activating signals leading to co-stimulation of intratu-
moral T cells [34–48].
After the viral lysis of tumor cells, tumor associated
antigens are released within the vicinity of the tumor,
resulting in the induction of mounting, sustained, specific,
and often CD8+ T cell-mediated antitumor responses.
However, an initial host response to the virus may result
in the rapid clearance of the virus before it manages to
replicate and infect tumor cells at a magnitude that will
ensure the initiation of an efficient vaccination response
[28]. Circumvention of this initial response has been
achieved using strategies such as PEGylation (covalent
conjugation with polyethylene glycol) of the viral coat and
polymer coating, which prevent antibody binding and
neutralization [49, 50]. Other strategies include the ex-
pression of viral gene products, which inhibit antigen
presentation, thus preventing recognition by T cells and
extending viral infection or the suppression of the host
immune system through pretreatment with cyclophospha-
mide [51, 52].
Numerous viruses have been tested as vectors for
OV immunotherapy. Some of them are naturally non-
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pathogenic to humans, such as Newcastle disease virus
(paramyxovirus), reovirus, and Seneca valley virus (picorna-
virus). Others, including herpes simplex virus, measles virus
(paramyxovirus), vaccinia virus (poxvirus), are genetically
manipulated to become non-pathogenic [53].
Thus far, the most advanced agent in clinical develop-
ment is Talimogene laherparepvec (T-VEC), which has
recently been approved by the FDA for the treatment of
advanced melanoma [54]. T-VEC is a modified oncolytic
herpes simplex virus type 1 [34, 55] in which two
ICP34.5 genes are deleted to prevent neuronal involvement.
These genes have been replaced by the coding sequence for
the cytokine GM-CSF [34]. Enhanced local expression and
secretion of GM-CSF favors APC recruitment to the tumor
microenvironment, thereby promoting the induction of an-
titumor immunity [34, 35, 56]. Further, ICP47 deletion in
T-VEC induces viral replication, enhances antigen presenta-
tion, and increases oncolytic therapeutic activity [34, 55].
Following preclinical studies which demonstrated the
therapeutic activity of T-VEC in several tumor cell lines
[35] and in animal models [34], T-VEC was evaluated in
a phase I clinical trial which enrolled patients with a
number of different tumor types [36]. The study opti-
mized the virus dose, confirmed good tolerability, and
demonstrated evidence of antitumor effect. A phase II
multi-institutional study was then conducted in which
50 patients with unresectable stage IIIC or IV melanoma
were enrolled [57, 58]. Patients received 106 pfu/mL T-
VEC by intratumoral injection as an initial dose and
3 weeks later they were administered 108 pfu/mL every
2 weeks for up to 24 injections. The study demonstrated
an objective response rate of 26 % with mild side effects
related to fever, fatigue and local injection site reactions.
These findings supported a prospective, randomized
clinical phase III trial that enrolled 439 patients with
unresectable melanoma (stages IIIb, IIIc, or IV) [59].
This study randomized subjects 2:1 to T-VEC or GM-
CSF and aimed for a durable response rate as the pri-
mary end point. The study demonstrated a substantially
better durable response rate for T-VEC compared with
the control arm (16.3 vs. 2.1; P < 0.001) and, although the
study was not powered for survival, the overall survival
was superior in the T-VEC arm. Finally, treatment was
well tolerated with only mild side effects, the majority of
which were related to fever, fatigue, nausea, and local site
reaction. Given these findings, the FDA approved T-VEC
to treat advanced melanoma in October 2015 [54]. T-VEC
is now the first oncolytic immunotherapy to be approved
worldwide and it provides a supplementary option for the
treatment of patients with advanced melanoma in addition
to the other already approved drugs.
Although promising, there are limitations associated
with oncolytic therapy. For instance, immunocomprom-
ised patients might not be good candidates because
OV-mediated antitumor immunity could be compro-
mised in these patients [28]. Furthermore, while T-VEC
is, in comparison with other cancer immunotherapy
strategies, a very low toxicity option, there is a limita-
tion regarding the levels of efficiency observed in pa-
tients with more advanced disease [28, 29, 31, 57]. For
these patients, T-VEC is not likely to be the best option
as a monotherapy but its administration combined with
cancer immunotherapy could prove particularly effect-
ive [28]. The fact that OVs are injected locally into the
tumor to avoid pre-existing antiviral immunity is also
considered a limitation because, in this case, the virus
may not reach tumors in organs that are difficult to
reach with an injection [29, 54]. Therefore, and given
the disseminated nature of metastatic cancer, it is be-
lieved that systemic administration may ultimately be
more effective. Despite the restraints, OV therapy has
demonstrated a favorable risk-benefit ratio and its ap-
proval by the FDA is a considerable milestone in the
field [28, 54].
Adoptive cell therapy
ACT is a promising form of immunotherapy which exploits
the antitumor properties of lymphocytes to eradicate pri-
mary and metastatic tumor cells [60]. Lymphocytes are
firstly isolated from patients’ peripheral blood, tumor-
draining lymph nodes or tumor tissue, expanded ex vivo,
and reinfused back into the patient [3, 61]. This strategy
would, in theory, circumvent the baffling duty of breaking
tolerance to tumor antigens and produce a large amount of
high avidity effector T cells [5]. Indeed, over the last two to
three decades, autologous T cell therapies have demon-
strated their potential to induce dramatic clinical responses
(and have become a viable therapeutic option) [61, 62].
ACT with tumor-infiltrating lymphocytes (TILs) is an
approach where T cells, generally mixtures of CD8+ and
CD4+ T cells grown from resected metastatic tumor de-
posits, are harvested and expanded ex vivo prior to
adoptive transfer [61, 63]. This approach attempts to re-
verse the functional impairment of the tumor-specific T
cells that reside within the tumor, and caused by the im-
mune suppressive tumor microenvironment, by growing
them prior to the reinfusion in a cocktail of various
cytokines [62].
The inclusion of a lymphodepleting conditioning regi-
men for patients prior to TIL infusion has resulted in
durable, complete regression of melanoma [61, 64–66].
Host lymphodepletion is speculated to improve TIL
functionality not only by eliminating immunosuppressive
cells, such as Treg and myeloid-derived suppressor cells
(MDSCs), in the tumor microenvironment but also by
increasing levels of homeostatic cytokines IL-7 and IL-15
[67, 68]. In a series of recent clinical trials, [69] 93 patients
with metastatic melanoma refractory to standard therapies
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were infused with autologous TILs in conjunction with IL-
2 administration following three different lymphocondi-
tioning regimens. The objective response rates ranged
from 49 % to 72 % and the rate increased with a greater
degree of lymph depletion. A complete tumor regression
was observed in 20 of 93 patients (22 %) and this response
was durable, continuing for 37 to 82 months in 19 (95 %)
of those 20 patients [69]. Other centers involved in large
scale trials (such as the MD Anderson Cancer Centre and
the Sheba Medical Centre) have reported consistently high
response rates and long-lasting tumor regression following
TIL therapy [64].
Despite those encouraging results, ACT with TILs has
some obvious disadvantages. Firstly, while lymphodeple-
tion enhances ACT efficacy, especially when ablative ra-
diation therapy is added to the conditioning regimen, it
can also be life-threatening and it is still not clear which
patients should be considered for this [64]. Other disad-
vantages include the cost and time required to develop
the desired cell populations [70]. Furthermore, applica-
tion of TIL therapy has been restricted to melanoma.
TILs can be isolated from several cancers, however, only
those from melanomas consistently carry selective reactivity
against the tumors from which they were generated, and
melanoma is the only cancer for which TILs have demon-
strated clinical activity. It has been suggested that the
heightened immunogenicity of melanoma compared with
other malignancies is associated with the high frequency of
mutational events in this cancer [61].
Ongoing efforts aim not only at improving TIL ther-
apy but also on broadening TIL to battle malignancies.
Advances in T cell culturing methods and genetic T cell
engineering ensure that clinically relevant numbers of
tumor-specific T cells can be generated and delivered as
therapy in a timely manner. There are two basic strat-
egies that are being explored in clinical testing of engi-
neered T cells. The first strategy involves the expression
of T cell receptor (TCR) α and β chains that confer the
engineered T cell with antigen-specificity of the trans-
ferred TCR (Fig. 2). This therapy is potentially accessible
to any patient whose tumor carries the cognate human
leukocyte antigen allele and expresses the target antigen
recognized by the TCR. However, the clinical use of
highly avid TCRs has been associated with significant
secondary destruction of healthy tissues expressing the
same target antigen. Ongoing efforts are focused on im-
proving gene transfer efficiencies, designing TCR struc-
tural modifications, and identifying target antigens that
Fig. 2 Genetic T cell engineering for the improvement and broadening of tumor-infiltrating lymphocyte (TIL) therapy. Chimeric antigen receptors
(CARs) consist of an Ig variable extracellular domain fused to a T cell receptor (TCR) constant domain. The engineered T cells obtain the antigen-
recognition properties of antibodies and thus are targeted against any potential cell surface target antigen. The expression of the TCR confers the
engineered T cell with the antigen specificity of the transferred TCR. TIL therapy with TCRs is feasible for patients whose tumor harbors the
human leukocyte antigen (HLA) allele and expresses the target antigen recognized by the TCR
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are highly selective for tumor cells rather than normal
cells [71]. Chimeric antigen receptors (CARs) constitute
the second approach and consist of an Ig variable do-
main fused to a TCR constant domain (Fig. 2). The ad-
vent of CARs omits the need for tumor cells to carry a
functional antigen processing machinery or to express
antigens through MHC class molecules since the engi-
neered T cells obtain the antigen-recognition properties
of antibodies and are thus potentially targeted against
any cell surface target antigen [72].
Tumor regression following administration of genetic-
ally engineered cells has been observed in B-cell malig-
nancies, melanoma, and synovial sarcoma, and trials in
other types of cancer are ongoing [61]. However, safety
issues regarding the selection of the target, the paucity
of such targets, serious adverse effects and the lack of
long-lasting responses in many patients implies that
additional interventions are warranted to appropriately
control and activate T cells in the tumor milieu [5].
Immune checkpoint blockade
Human cancers carry a multitude of somatic gene muta-
tions and epigenetically altered genes, the products of
which are potentially recognizable as foreign antigens.
Although an endogenous immune response to cancer is
observed in preclinical models and patients, this re-
sponse is not efficient because tumors induce tolerance
among tumor-specific T cells and by expressing ligands
that bind inhibitory receptors and dampen T cell func-
tions within the tumor microenvironment [3, 5, 73].
One approach to trigger antitumor immune responses
has been termed “checkpoint blockade”, referring to the
blockade of immune-inhibitory pathways activated by
cancer cells [7].
CTLA-4, an inhibitory receptor that down-regulates
the initial stages of T cell activation (Fig. 3a), was the
initial target for checkpoint antibodies [74–76]. The ra-
tionale for using anti-CTLA-4 in cancer therapy was to
unleash pre-existing anticancer T cell responses (Fig. 3b)
and possibly trigger new ones [5, 77]. Antagonist anti-
CTLA-4 monoclonal antibodies exhibited antitumor
properties in several murine tumor models, such as such
as cancers of the ovary, bladder, brain, and fibrosarcoma,
while CTLA-4 blockade was ineffective in B16 melan-
oma, SM1 mammary carcinoma, EL4 lymphoma, M109
lung cancer, and MOPC-315 plasmacytoma models [78].
Ipilimumab, an anti-CTLA-4 antibody, was approved by
the FDA in 2011 as a first-line therapy for melanoma pa-
tients with metastatic disease, based on phase III trials
that showed prolongation of overall survival [4, 13, 79].
Although only a relatively small fraction of patients ob-
tained clinical benefit, these studies clearly establish ipili-
mumab as an active reagent, offering patients clinically
significant benefits and the possibility for long-lasting
survival at what is normally the terminal stage of the
disease. Additionally, the results validate the idea that
activating the T cell compartment can, on its own, pro-
vide significant therapeutic benefit [5].
Despite the aforementioned encouraging results, the
usage of ipilimumab has shown clinical and scientific
challenges. Firstly, as anticipated by the lethal auto-
immune phenotype of CTLA-4 knockout mice, grades
3–5 (severe) immune-related adverse events have been
observed in 10–35 % of patients undergoing CTLA-4
blockade [80]. The lack of specificity in T cell expansion,
coupled with the fundamental importance of CTLA-4 as
an immune checkpoint, could account for the significant
immune-related toxicities observed in patients treated
with ipilimumab [13]. Secondly, in contrast to conven-
tional cytotoxic therapies that directly attack cancer cells
and result in a rapid decrease in tumor size, response
characteristics with ipilimumab may take several months
a b
Fig. 3 T cell activation in the lymph node. a Both immunological signal 1 (T cell receptor (TCR) recognition of antigens) and immunological
signal 2 (stimulation of CD28 by B7 costimulatory molecules) are required for T cell activation in the lymph node. The interaction between the
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) receptor and B7 expressed on T cells and antigen presenting cells, respectively, prevents T
cells from becoming fully activated by blocking immunologic signal 2. b Antibodies that block the CTLA-4 pathway (e.g. ipilimumab) permit T cell
activation by derepressing signaling by CD28. MCH, Major histocompatibility complex. (Adapted from [77])
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to manifest, making it difficult to assess response [5].
Nevertheless, ipilimumab has not only provided realistic
hope for melanoma patients, especially those with end-
stage disease [5], but has initiated a great effort in the
search for other immune modulators that can achieve
what ipilimumab can, but in a more selective and harm-
less fashion, with the potential for greater efficiency and
frequency of response, and with less autoimmune-
related side effects [11].
The downstream signaling of the PD1 receptor, another
inhibitory receptor expressed by antigen-stimulated T
cells, inhibits T cell proliferation, cytokine release, and
cytotoxicity [81–83]. PD1 has two known ligands, PD-L1
and PD-L2 [84, 85]. In tumor models, PD1 signaling in-
hibits T cells and blocks the antitumor immune response
after binding to PD-L1 expressed within the tumor
(Fig. 4a) [5]. Inhibition of the interaction between PD1
and PD-L1 (Fig. 4b) can enhance T cell responses in vitro
and mediate (preclinical) antitumor activity [86]. Anti-
bodies targeting PD1 or PD-L1 have reached the clinic
and include pembrolizumab (previously named as lambro-
lizumab; anti-PD1) and nivolumab (anti-PD1) [11]. In
early phase I trials, PD1-PD-L1 axis blockade alone has
yielded promising results in a variety of cancer types; in
melanoma, the anti-PD1 antibody nivolumab has shown
sufficient clinical responses which are often durable, with
some patients remaining free from disease progression for
many years [87]. The anti-PD-L1 antibody atezolizumab
has induced therapeutic responses in patients within a
broad range of human cancers, which included lung,
colon, head and neck, and gastric cancers in addition to
melanoma and renal cell carcinoma. Thus far, both pem-
brolizumab and nivolumab have been FDA approved for
the treatment of melanoma and NSCLC, while nivolumab
has been also approved for the treatment of renal cell car-
cinoma [4].
These data are consistent with the suggested mechanism
of action of this negative regulator. Although CTLA-4 reg-
ulates de novo immune responses, the PD1 pathway exerts
its major influence on ongoing (effector) immune re-
sponses [3]. Particularly, the interaction between PD1 and
PD-L1 expressed on activated effector T cells results in in-
activation of the PI3 kinase signaling cascade [88, 89] and
subsequent blockage of the secretion or production of
cytotoxic mediators required for killing. However, it seems
that this blockage is rapidly reversible once the inhibition
is lifted. Most importantly, the PD-L1 and PD1 antago-
nists have demonstrated significant response rates and re-
markably long-lasting responses [11].
The most striking contrast of the agents that target
the PD1-PD-L1 axis to the therapies that block CTLA-4
(ipilimumab) is the favorable toxicity profile of the PD1-
PD-L1 blocking agents [90]. The majority of reported
cases of toxicity have been readily manageable with
supportive care or by immune suppression with steroid
administration [11]. The reduced toxicity is consistent
with the distinct phenotypes of PD1 genetic knockout
mice, which develop delayed-onset organ-specific inflam-
mation as opposed to the uncontrolled global T cell prolif-
eration seen in CTLA-4 knockouts [3], and might hint at
the benefits of specifically targeting the properties of cancer
that inhibit the immune response rather than non-specific
activation of the immune system [11].
Multiple other immune checkpoint pathways that could
be the target of novel therapies have been identified. A few
examples of those newly discovered molecules that are
now being evaluated in preclinical tumor models and/or
even in clinical trials are lymphocyte activation gene 3
a b
Fig. 4 T cell activation in the tumor milieu. a Programmed cell death protein 1 (PD1) receptor is an inhibitory receptor expressed by antigen-
stimulated T cells. Interactions between PD1 and its ligand, PD-L1, expressed in many tumors activate signaling pathways that inhibit T-cell activity
and thus block the antitumor immune response. b Antibodies targeting PD1 or PD-L1 block the PD1 pathway and reactivate T cell activity. MCH,
Major histocompatibility complex; TCR, T cell receptor. (Adapted from [77])
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(LAG3) protein [91] and T cell immunoglobulin and
mucin domain-containing 3 (TIM3) protein [92]. From
these, therapies targeting LAG3 are the furthest along in
clinical development. LAG3 was identified to be progres-
sively expressed on T cells during exhaustion [93] and to
be a selective marker of T reg cells, suggesting that it may
play a role in immune suppression by tumors. On account
of these results, it was speculated that inhibiting LAG3
could enhance antitumor immunity by reversing T cell ex-
haustion. Agents targeting LAG3, including a fusion pro-
tein and LAG3-specific antibodies, have been developed
and tested in the clinic either as monotherapy [94] or in
combination with anti-PD1 or with conventional therapies
[95], demonstrating encouraging results [4]. Human TIM3
is expressed by various T cell populations and by innate
immune cells such as DCs [96]. TIM3 coexpression with
PD1 on CD8+ tumor infiltrating T cells hinted at the
importance of TIM3 in the cancer setting and implied
that combination therapies targeting both these path-
ways are worth exploring [92]. TIM3 antagonists have
not been tested in clinical trials but several are in pre-
clinical development [2]. These molecules are just two
representatives of the numerous immune checkpoint
agents that are currently under development for clinical
testing and that are anticipated to improve the antitu-
mor responses when used in combination with other
immunologic modalities [4].
Combination therapies
Combining immune checkpoint inhibitors
A subgroup of patients with advanced cancers may respond
to single-agent immunotherapy, but for the majority,
monotherapy may be relatively ineffective [2]. It is thought
that, in order to achieve complete remission and cures for
patients with cancer, the combination of multiple thera-
peutic approaches may be required. This field is progressing
rapidly to the point that new combinations are being
assessed almost monthly [97]. In the following sections, we
will mention only a few of the main immunotherapy com-
binations that have been tested thus far, the successes and
failures related to them, and the limitations regarding their
administration.
Although both CTLA-4 and PD1 are expressed on T
lymphocytes, these negative regulators affect different
signaling pathways within these cells; the CTLA-4 check-
point plays a major role in dampening T cell priming and
activation, whereas PD1 blocks effector T cell responses
within tissues [3]. Thus, the combination of anti-CTLA-4
and anti-PD1 therapies has been anticipated to demon-
strate synergy. Indeed, combination therapy with anti-
bodies targeting both molecules was tested and found
to improve antitumor responses in a preclinical animal
model [98].
A phase I clinical trial with ipilimumab (anti-CTLA-4)
combined with nivolumab (anti-PD1) reported tumor
regression in 50 % of treated patients with advanced
melanoma [99]. A more recent randomized, placebo-
controlled phase II study comparing ipilimumab com-
bined with nivolumab versus ipilimumab alone reported
even better responses. Patients with previously untreated
metastatic melanoma who received the combination treat-
ment showed an objective response rate of 61 % while, of
the patients assigned to the ipilimumab monotherapy,
only 11 % demonstrated an objective response [99]. Ac-
cording to a recent, randomized, three-arm phase III
clinical trial which compared monotherapy with either
ipilimumab or nivolumab to their combination in pa-
tients with melanoma, nivolumab alone was less toxic
and showed greater clinical benefit than ipilimumab
alone [100]. Nivolumab as monotherapy and in com-
bination with ipilimumab demonstrated better objective
response rates compared to ipilimumab. From this
study the overall survival results are anticipated to shed
light on the full effect of combination immunotherapy.
On account of these promising efficacy results, there are
ongoing clinical trials with anti-CTLA-4 (ipilimumab,
Bristol-Myers Squibb or tremelimumab) plus anti-PD1 or
anti-PD-L1 in other tumor types such as renal cell carcin-
oma, NSCLC, small-cell lung, triple-negative breast, pan-
creatic, gastric, and bladder cancer [97].
Although the combination of immune checkpoint in-
hibitory antibodies may increase/enhance antitumor im-
munity, it may also lead to an increase in the magnitude,
frequency, and onset of side effects and toxicities (com-
pared with prior experience with either antibody alone)
[11]. These side effects resemble autoimmune diseases
(such as dermatitis, inflammatory colitis, hepatitis, hypo-
physitis, and thyroiditis) and, although they can be usually
managed with the administration of treatment involving
immunosuppression, they clearly identify a requirement
for careful dose titrations to define windows of clinical ef-
ficacy [3]. Additionally, little is currently known about the
long-term effects of combination therapy and whether a
different range of immune-mediated toxic effects will
manifest with chronic exposure.
Combination therapy of immune checkpoint inhibitors
with conventional therapies
The effects of chemotherapy have always been seen as
necessarily harmful to immune mechanisms, however, it
is now known that these effects are rather drug-, dose-,
and/or schedule-dependent [3]. Conventional cytotoxic
treatment regimes, such as chemotherapy, may, in fact, po-
tentiate the antitumor response by releasing multiple tumor
neoantigens [101–104]. Chemotherapy may also boost im-
munotherapies in patients by modifying the immunosup-
pressive environment of the tumor. Cyclophosphamide is
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known for depleting Treg cells [105], whereas other chemo-
therapeutic agents, such as paclitaxel and 5-fluorouracil,
eliminate MDSCs [106, 107]. By eliminating the immuno-
suppressive activities of tumor infiltrating Treg cells
and MDSCs, chemotherapy enhances antitumor T cell
functions and may lead to more effective inductions of
antitumor immune responses [2]. Additionally, combin-
ing immune checkpoint inhibitors with chemotherapy
may take advantage of the reduction of tumor burden
caused by chemotherapy [102]. On the other hand, cau-
tion is required when designing clinical protocols because
the same agent may prove to be inhibitory, benign, or even
stimulatory depending on the phase of immune response
being targeted, and even the dose or schedule used
[108, 109]. There are chemotherapy regimens that sup-
press proliferating lymphocytes and could possibly have
a negative influence on the effectiveness of immune
checkpoint inhibitors that promote the proliferation
and activation of TILs. Thus, great care must be taken
to use such agents at doses and schedules that do not
deplete effector CTLs [5].
This type of combined therapy can lead to an increase
in the frequency of adverse events. It has been shown
that the combination of ipilimumab with dacarbazine re-
sulted in a survival benefit compared to dacarbazine alone,
but this combination therapy had to be discontinued due
to synergistic toxicity being observed in several patients
[79]. A couple of clinical trials have been completed and
many more are ongoing investigating the efficacy and tox-
icity that can be generated by this combination [97].
Similarly to chemotherapy, molecularly targeted ther-
apies expose neoantigens during tumor cell death and
they boost/facilitate the antitumor response by priming
de novo T cell responses (Fig. 5). The difference is that,
while chemotherapy leads to the destruction not only of
tumors but also of normal cells, resulting in potential im-
mune response against self-antigens expressed on normal
tissues, molecularly targeted therapies, by attacking cancer
cells with specific genetic characteristics, restrict the acti-
vated immune response generated by immunotherapy
agents specifically on tumor antigens. This, in theory,
should result in fewer adverse effects [4].
For melanoma patients carrying the V600E activating
mutation of B-Raf, treatment with the FDA-approved
B-Raf inhibitor vemurafenib has been demonstrated to
produce impressive responses in more than half of the
patients [110]. However, the development of resistance
in some patients requires the administration of a sup-
plementary therapy, which ideally should not simply in-
volve the administration of another inhibitor targeting
Fig. 5 Combination therapy of immune checkpoint inhibitors with conventional therapies may enhance antitumor responses. Molecularly
targeted therapies attack cells with specific genetic characteristics resulting in the release of multiple tumor neoantigens. Tumor neoantigens are
taken up by antigen presenting cells that then present them in the context of B7 costimulatory molecules and major histocompatibility complex
to T cells. T cells are partially activated but overexpress checkpoint molecules, such as CTLA-4 and PD1, which prevent them from becoming fully
activated at the tumor site. Immune checkpoint blockade unleashes pre-existing anticancer T cell responses and licenses T cells to attack the cancer
cells. CTLA-4, Cytotoxic T lymphocyte-associated protein 4; MCH, Major histocompatibility complex; PD1, Programmed cell death protein 1; PD-L1, PD1
ligand; TCR, T cell receptor. (Adapted from [4])
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compensatory pathways (e.g. MEK inhibitor), since the
tumor could also easily bypass this strategy. The goal is to
generate durable responses and, since immune checkpoint
inhibitors have been proven to induce long-term remission,
the combination of those two modalities seemed a rational
match [5]. Numerous combinations have been attempted
with mixed success, and additional combinations are being
explored on an ongoing basis. Here are some samples of
trials that have already been performed. A phase I clinical
trial testing the B-raf inhibitor vemurafenib combined with
the anti-CTLA-4 antibody ipilimumab was terminated early
due to hepatotoxicity [111]; however, preliminary data from
a combination trial of ipilimumab with the BRAF inhibitor
dabrafenib indicate that this combination can be tolerable
[112]. Nevertheless, triple therapy with ipilimumab, dabra-
fenib, and trametinib led to colitis in two out of seven
patients enrolled in the study. Although the number of
patients was small, these cases highlighted the increased
possibility of added toxicity with the triple combination
over ipilimumab as a single agent and the triple combin-
ation cohort of this study was closed [113].
The combination of PD1-PD-L1 axis blockade with B-raf
inhibitors alone or in combination with MEK inhibitors is
presently being investigated. This approach is based on ob-
servations such as the development of resistance to B-Raf
inhibitors accompanied by an upregulation of PD-L1 on
melanoma cells and the influx of TILs in biopsy samples
taken soon after the initiation of BRAF-V600E inhibition in
patients with melanoma [114].
Immune checkpoint inhibitors have also been com-
bined with vascular endothelial growth factor (VEGF)-
guided therapy. The rationale behind this combination is
that, besides promoting angiogenesis, VEGF plays a part
in immunity by enhancing the number of Treg cells and
MDSCs in the tumor while reducing the intratumoral
influx of lymphocytes and suppressing DC maturation.
A few studies targeting either the VEGF receptor or VEGF
combined with immune checkpoint inhibitors have already
been conducted and the results were encouraging [2]. A
phase I clinical trial showed that the combination of nivolu-
mab with either sunitinib or pazopanib as a second-line
therapy in patients with kidney cancer generated high re-
sponse rates for both arms [115]. Increased but manageable
grade 3–4 toxicities were observed in both combinations,
highlighting that further adjustments in dose and schedule
may be required to define an optimal regime [97].
According to a study recently published by Hodi et al.
[116], the combination of CTLA-4 blockade with ipili-
mumab and VEGF inhibition with bevacizumab in pa-
tients with metastatic melanoma exhibited favorable
clinical activity compared with ipilimumab alone, leading
to a median survival of 25 months. Side effects included
inflammatory events such as giant cell arteritis, hepatitis,
and uveitis and, although they were more frequent than
anticipated for either drug alone, they were controllable
[116]. Bevacizumab combined with the PD-L1-specific
monoclonal antibody (mAb) atezolizumab has generated
moderate adverse effects in phase I clinical trials [2].
Additional studies have targeted VEGF signaling through
neuropilin receptors based on the expression of the lat-
ter on a subset of Treg cells and on a specific subgroup
of dendritic cells and because neuropilin is upregulated
in numerous tumor types with expression being correlated
with tumor progression [117–119]. The phase I study of
the human mAb MNRP1685A, which targets the VEGF-
binding domain of neuropilin1 (NRP1), in patients with
advanced solid tumors, showed tolerability [120], while a
phase Ib study evaluating an anti-NRP1 mAb, in combin-
ation with bevacizumab and paclitaxel in patients with ad-
vanced solid tumors, generated a higher than expected
proteinuria [121]. This outcome weakens the further testing
of anti-NRP1 agent combined with VEGF targeted regimes.
Combination of immunostimulatory antibodies
Immunostimulatory antibodies represent another class
of agents that have been tested either as monotherapy or
in combination with the immune checkpoint inhibitors.
Most of these target members of the TNF receptor
superfamily and, in contrast to immune checkpoint tar-
gets such as PD1 or CTLA-4, the goal of most of these
antibodies is to activate their target receptors. Thus far,
antibodies stimulating the OX40 and 4-1BB receptors
are furthest along in clinical development [4]. 4-1BB is
an inducible type I membrane glycoprotein expressed on
the surface of primed CD4+ and CD8+ T cells. Numerous
studies indicate that signaling via 4-1BB either by binding
to its ligand or by antibody ligation promotes T cell
activation, growth, and survival and enhances effector
functions [122].
The significance of the 4-1BB pathway has been
highlighted in numerous diseases, including cancer, and
it has been previously shown that anti-4-1BB mAbs
possess potent antitumor properties derived from their
effectiveness in activating and protecting T and NK
cells [123]. Urelumab and PF-05082566 are agonistic 4-
1BB-specific antibodies that are under evaluation for
several malignancies. Although some antitumor activity
was observed for urelumab during a phase I trial [124],
a phase II trial in patients with melanoma resulted in
increased hepatotoxicity leading to therapy discontinu-
ation [2]. Testing of PF-05082566, either as monotherapy
or combined with rituximab, exhibited some encouraging
results in mixed solid tumors and in non-Hodgkin lymph-
oma in phase I clinical trials [2].
Interestingly, a recent study showed that tumor-
targeting antibodies, such as cetuximab or trastuzumab,
induced the upregulation of 4-1BB on NK cells and,
when NK cells were stimulated with an agonist 4-1BB
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antibody, they exhibited an improved cytotoxicity against
cancer cells [87]. Thus, preclinical evidence supports the
hypothesis that the combination of 4-1BB-specific mAbs
with tumor depleting antibodies will show potent syner-
gistic effects [125].
The effects of coupling anti-4-1BB agonist antibodies
with immune checkpoint blockade/inhibitors have also
been investigated. CTLA-4 inhibition combined with
the “trimab” scheme (composed of immune activating
anti-CD40 and anti-CD137 mAbs, a blocking antibody
against the DR5 receptor for TNR-related apoptosis indu-
cing ligand) substantially increased the tumor rejection
rate of established mammary tumors in mice compared to
trimab alone [126].
According to more recent studies, combining T cell
co-inhibitory blockade with anti-CTLA-4 and active
co-stimulation with anti-4-1BB promotes rejection and
regression of B16 melanoma and prostate tumors, respect-
ively, in the context of a suitable vaccine [127, 128]. Add-
itionally, agonistic anti-4-1BB antibodies combined with
anti-PD1 can enhance the curative capacity of radiother-
apy in established breast malignancy [129]. While it is still
early, the aforementioned data indicate that the parallel
targeting of the immune checkpoint blockade and 4-1BB
signaling pathways justifies clinical evaluation [130].
OX40 is a potent costimulatory receptor found pri-
marily on CD4+ and CD8+ T cells and its engagement
promotes T cell activation, survival, proliferation, and
cytokine production [131, 132]. The natural ligand of
OX40 is found on APCs, including DCs, B cells, and
macrophages, and also on activated T cells. The expres-
sion pattern of those two molecules suggests that the
OX40 pathway supports the immune response during T
cell activation. Preclinical studies have shown that mono-
therapy with an OX40 agonist mediated the rejection of
various tumors [131–134]. According to the first phase I
clinical trial, patients with advanced cancer treated with
an agonistic OX40 mAb experienced an acceptable tox-
icity profile and 12 out of 30 patients showed regression of
at least one metastatic lesion [131].
In an attempt to improve the efficacy of OX40 engage-
ment, OX40 agonist antibodies have been paired with
chemotherapy, radiotherapy, targeted small-molecule
therapeutics, cytokines and adjuvants, immune stimula-
tory antibodies such as agonist 4-1BB mAbs, and im-
mune checkpoint inhibitors against CTLA-4, PD1, and
TIM3. The preclinical data showed that those combined
schemes improved tumor rejection, long-term survival,
and/or resistance to tumor rechallenge in mice bearing
various cancers [2, 130].
Glucocorticoid-induced tumor necrosis factor receptor
related gene (GITR) is a costimulatory molecule constitu-
tively expressed on Treg cells. Contrary to Tregs, CD4+
and CD8+ T cells begin to express GITR approximately
24 hours after stimulation, with the expression lasting sev-
eral days. GITR has also been observed on DCs, mono-
cytes, and NK cells. The GITR ligand is highly expressed
on activated APCs and endothelial cells [2, 130]. GITR
seems to play a key role in suppressing Treg cell activity,
activating proliferation, and in effector functions in
CD4+ and CD8+ cells [97]. Preclinical research has
demonstrated that activating GITR, by agonist antibodies
or natural ligands, can also serve as an effective antitumor
therapy [135].
In vitro GITR ligation has previously been shown to
augment T cell-mediated antitumor immunity. Cohen et
al. [136] were the first to demonstrate that, as a monother-
apy, an agonist anti-GITR antibody induced regression of
small established B16 melanoma tumors in mice. The
GITR agonist was shown to synergize with anti-PD1
therapy to eliminate established tumors [2] and it has
also been successfully coupled with other immuno-
therapies such as DC-based vaccines, adoptive cell
transfer, or an antagonistic antibody against CTLA-4
[130]. Although the clinical development of GITR-specific
antibodies is limited to date [2], the aforementioned find-
ings provide further support for the continued development
of agonistic anti-GITR mAbs as an immunotherapeutic
strategy for cancer and antibodies from GITR Inc., Merck,
Agenus, and others are in preclinical and early clinical
development [2].
Herpes virus entry mediator (HVEM) is another mem-
ber of the TNFR superfamily widely expressed on APCs,
endothelium, and lymphocytes, with the highest expression
levels detected on resting T cells [2, 130]. As a molecular
switch, HVEM regulates T cell activation in a costimulatory
or coinhibitory fashion depending on which ligand it has
engaged [137]. HVEM ligands belong to two distinct fam-
ilies: the TNF-related cytokines LIGHT and lymphotoxin-α,
and the Ig-related membrane proteins BTLA and CD160
[138, 139]. The binding of LIGHT or lymphotoxin-α to
HVEM delivers a stimulatory signal, whereas the bind-
ing of BTLA or CD160 to HVEM delivers an inhibitory
signal [137].
HVEM and its ligands have been involved in the
pathogenesis of various autoimmune and inflammatory
diseases, but recent reports indicate that this signaling
pathway may also be involved in tumor progression and
resistance to immune response [138, 139]. For instance,
it has been shown that BTLA weakens antitumor T cell
activation by signaling via HVEM [138, 140] and BTLA
inhibition augmented the propagation and antitumor
activity of melanoma-specific CD8+ T cells [141]. Add-
itionally, BTLA is upregulated in various tumor types,
suggesting that this pathway has been appointed for
use in immune suppression. Due to these observations,
approaches to mono- or combination therapy targeting
the HVEM axis have been suggested and therapeutic
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targeting of the HVEM axis is likely to see clinical de-
velopment in the near future [2].
The combination of immune checkpoint inhibitors
with cancer vaccines was anticipated to elicit a robust
response in clinical trials. Although some encouraging
results have been reported in mouse models and clinical
trials [11, 142], this approach has not yet flourished.
What has also been proposed and tested is the combin-
ation of immune checkpoint inhibitors with OVs. OVs
were initially designed to act as tumor-eliminating thera-
peutics, but the most recently engineered OVs not only
induce immunogenic cell death but also express immune
stimulating “cargo” that can be selectively targeted to
tumor beds. The coupling of agents that block the im-
mune checkpoint with OVs has been viewed as a natural
marriage demonstrated in preclinical models by combin-
ing Newcastle disease virus with antibodies against the
CTLA-4 receptor [143]. The combination of T-VEC and
immune checkpoint blockade has significant preclinical
support, it has already been tested in the clinic and large
randomized studies are underway. Preliminary data from
a phase I trial of T-VEC and ipilimumab did not demon-
strate unexpected side effects, while they have reported
response rates of 50 % with a 22 % complete response
rate, thereby supporting an added therapeutic benefit of
combination therapy [144]. Based on these results, a
randomized phase II study of ipilimumab plus T-VEC
versus ipilimumab alone is ongoing, with target accrual
of 200 patients (NCT01740297) [145], while a random-
ized phase I/II study of pembrolizumab with or without
T-VEC is also underway [145].
A myriad of potential combination strategies exist, but
immune checkpoint blockade stands out as the back-
bone of most strategies (Table 2) [13, 100, 146–151].
The main reason is that the immunologic checkpoint
inhibitors have continued to show efficacy in a broad
variety of tumor types, including those characterized as
poorly immunogenic. Nevertheless, while combin-
ational immunotherapies have been quite successful so
far, we should not think of them as a panacea. The
exact mechanisms for the antitumor effects of these
therapies in murine and human tumors remain obscure
and, therefore, their combinations may lead to unfore-
seen consequences.
Another issue that has also been addressed is the ap-
propriate scheduling of the combined therapies. Some
argue that (molecularly) targeted therapies and immuno-
therapy will not necessarily offer the optimum result in
terms of efficacy and safety simply by combining them
at the same time. This is supported by the fact that not
only do some molecularly targeted therapies also have
mmunomodulatory effects, but mutations introduced
by some chemotherapies might render subsequent im-
munotherapies more effective. On the other hand, others
argue that it is not clear that a regressing tumor is im-
munogenic while growing tumors are known to induce
inflammatory processes. Thus, cancers may be the most
immunogenic while growing and immunotherapy
would not be as effective when given after a targeted
therapy [152].
What is obvious is that there are still several open
questions in cancer immunotherapy as reflected by the
empirical rather than rational manner through which
the synergistic effects of most of the agents are presently
discovered. A more complete understanding of the im-
mune mechanisms of these agents and of the way they
interact with the immune system and the tumor itself
are warranted to guide the development of combination
therapies for clinical trials.
Biomarkers in cancer immunotherapy
Immunotherapy has been a game-changer in the field of
cancer therapy and developments in immune checkpoint-
based therapy, in particular, are progressing at a breathtak-
ing pace. Nevertheless, only a fraction of patients respond
to these immunotherapies [153]. Therefore, patient selec-
tion is an important issue as it will avoid treatment-related
toxicity and cost in patients that are unlikely to benefit.
This will require the identification and validation of reliable
surrogate biomarkers that will provide an early indication
of response or predict clinical benefit.
There are several ongoing efforts to identify predictive
biomarkers of immune checkpoint therapy (Table 3).
Several studies support the hypothesis that immunother-
apy is particularly efficient in highly mutagenized tumors
[154, 155]. The mutational load is believed to generate
neo-antigen-specific T cell responses which are likely to
contribute to the clinical responses to immunotherapy.
For instance, according to two independent groups, the
mutational frequency in melanoma tumors was corre-
lated with clinical responses to anti-CTLA-4 therapy
[156]. Similarly, higher numbers of mutations, including
mutations in DNA repair pathways, were shown to correl-
ate with clinical responses in patients with colon cancer
and NSCLC who were treated with anti-PD1 inhibitors
[157, 158]. However, this is not the case for all tumor types
since, in different clinical trials, patients with kidney cancer,
which has a relatively low mutational frequency, have had
noticeable clinical responses to anti-PD1 treatment [159].
For many cancers the presence of lymphocyte infiltrates
is related to improved survival [97]. Additionally, it has
been suggested that PD-L1 expression on tumor cells may
potentially serve as a useful predictive biomarker to iden-
tify patients who would benefit from immune checkpoint
blockade monotherapy [86]. However, it has been subse-
quently shown that many patients with PD-L1-negative
tumors can still respond to PD1 pathway blockade while
some patients with high levels of PD-L1 do not respond
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[99, 160]. Therefore, the levels of PD-L1 around the tumor
microenvironment cannot be considered an optimal bio-
marker for patient selection and lack of PD-L1 expression
cannot be reliably used to exclude patients from treatment
with PD1 pathway blockade.
Current studies in several tumors are concentrated
on characterizing TILs, including the overexpression of
markers of exhaustion such as PD1, LAG3, and TIM3,
because, according to studies on murine models [92, 161],
the combination of those immune checkpoint inhibitors
Table 3 Immunotherapy biomarkers
Biomarker Comments Refs
Mutational load In general, the higher the number of mutations the better the response to immunotherapy; not the
case for all tumors
[154–159]
Lymphocyte infiltrates The presence of lymphocyte infiltrates is related to improved survival [2, 97]
PD-L1 expression PD-L1 expression on tumor cells may potentially serve as a useful predictive biomarker for response to
anti-PD1/PDL1 therapy; not the case for many tumors
[86, 99, 160]
Genetic profiling Patients with higher baseline expression of immune-related genes generally respond better to ipilimumab [97]
PD1, Programmed cell death protein 1; PD-L1, PD1 ligand
Table 2 Outcomes from key clinical trials of combination immunotherapies (adapted from [97])










945 -44 % nivolumab
-19 % ipilimumab
-58 % ipilimumab plus
nivolumab
Median PFS:
-2.9 months for ipilimumab*
-6.9 months for nivolumab†























142 -11 % ipilimumab*
-61 % ipilimumab plus
nivolumab*
Median PFS:
-4.4 months for ipilimumab








Ipilimumab or vaccine alone
versus ipilimumab plus vaccine
676 -10.9 % ipilimumab
alone*
-1.5 % vaccine alone†
-5.7 % ipilimumab with
vaccine*,†
Median OS:
-10.1 months for ipilimumab
alone
-6.4 months for vaccine alone*










502 -10.3 % dacarbazine
alone
-15.2 % ipilimumab with
dacarbazine
Median OS:
-9.1 months for dacarbazine
alone*











799 NA Median OS:
-10.0 months for radiotherapy
followed by placebo






NSCLC Placebo control versus phased
or concurrent schedule













ED-SCLC Placebo control versus phased
or concurrent schedule







-6.4 months for phased
ipilimumab*
[151]
The difference between pairs of outcomes marked by either * or † reached statistical significance
CR, Complete response; CRPC, Castrate-resistant prostate cancer; ED-SCLC; Extensive-disease small cell lung cancer; irBORR, Immune-related best overall
response rate; irPFS, Immune-related progression-free survival; NA, Not available or not presented; NSCLC, Non-small-cell lung cancer; OS, Overall survival;
PR, Partial response
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can be effective in overcoming this exhausted phenotype
[2, 92, 161]. What is also understood is that the response
to different immunotherapeutic combinations will prob-
ably rely on the patient’s immune milieu. Thus, the devel-
opment of a system that, apart from PD-L1 status and
lymphocyte profile, takes into consideration a wider pic-
ture of the immune milieu, will be critical in guiding
therapeutic combinations. Furthermore, the integration of
immunohistochemistry and genetic profiling of the tumor
microenvironment could be exploited to classify cancers
based on their strategy of immune evasion; this is antici-
pated to improve biomarker algorithms [2, 97].
Conclusion
Cancer therapy has long depended on strategies that dir-
ectly attack tumor cells to treat patients. Cancer im-
munotherapy, the treatment that harnesses the patient’s
immune system to fight cancer, is now emerging as an
important addition to conventional therapies. Immune
checkpoint blockade therapy, in particular, has undoubt-
edly been one of the most impressive advancements
made in cancer therapeutics in recent years. The impact
of this scientific achievement is reflected by the fact that
James P. Allison has been recently awarded the 2015
Lasker-DeBakey Clinical Medical Research Award for
the discovery and development of an anti-CTLA-4 mAb
that releases the brakes of the immune system to combat
cancer. Blockade of CTLA-4 with the mAb ipilimumab
has already benefited thousands of people with advanced
melanoma, a disease that typically used to kill people in
less than a year. Most importantly, the clinical success
of anti-CTLA-4 created a new field, termed immune
checkpoint therapy, and now, not only have additional
immune inhibitory checkpoints been released, such as
PD1 and its ligand PD-L1, but these are being used in
combination with each other or with conventional therap-
ies for the induction of robust and sustained antitumor
responses in a wide variety of tumors. While optimal com-
binations of regimes still need to be determined and ex-
tensive efforts must be made in the identification and
validation of predictive biomarkers, checkpoint blockade
immunotherapy and its combination with other (immune)
therapeutic modalities are the leading path to increased
therapeutic success across a whole range of tumor types.
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